Edward Kaplan, M.D.
- Colorectal Cancer
- Esophageal Cancer
- Stomach (Gastric) Cancer
- Pancreatic Cancer
- Hepatic and Biliary Duct Cancers
- Assistant Clinical Professor, Department of Medical Oncology & Therapeutics Research
- Referring Physicians Phone(847) 675-3900
- Referring Physicians Fax(847) 675-3030
Edward Kaplan, M.D., is a medical oncologist at City of Hope® Cancer Center North Shore, where he specializes in treating patients with colorectal, esophageal, gastric, biliary duct, hepatic and pancreatic cancer. With more than 30 years of experience in his field, Dr. Kaplan is committed to offering patients access to leading-edge treatment options, including precision medicine tools such as genomic testing and immunotherapy.
In his clinical work, Dr. Kaplan treats patients with a wide variety of cancer types and stages. In addition to gastrointestinal malignancies, he works with patients who are diagnosed with lung, breast, kidney, bladder, ovary, prostate and testicular cancer. He’s also passionate about improving cancer screening and risk management for people with inherited genetic mutations such as BRCA1 and BRCA2.
After earning his medical degree at Loyola University Chicago Stritch School of Medicine in Maywood, Illinois, Dr. Kaplan completed a residency in internal medicine at Northwestern University in Chicago, followed by subspecialty training in hematology-oncology at the same institution, where he was named both a Galter Fellow and a Bill Veek Fellow.
A physician-scholar, Dr. Kaplan has written or co-authored dozens of peer-reviewed articles on topics ranging from immunotherapy to clinical trial protocols and the psychological impacts of lung cancer. He’s been an assistant professor at Rush University’s medical school in Chicago, where he also cofounded and was director of the Rush Cancer Institute’s Comprehensive Center for Gastrointestinal Malignancies. Dr. Kaplan is also a board member with Sharsheret, the Jewish Breast and Ovarian Cancer Community.
Watch the video to discover what inspired Dr. Kaplan to pursue a career working with cancer patients, and why he feels medical oncology is his calling.
Location
North Shore
Morton Grove, IL 60053
Education & Experience
Board Certification
- Medical Oncology and Internal Medicine — American Board of Internal Medicine
Degree
- Loyola University Chicago Stritch School of Medicine, Maywood, IL
Fellowship
- Hematology/Oncology — Northwestern University Medical School, Chicago, IL
Residency
- Internal Medicine — Northwestern University Medical School, Chicago, IL
Awards & Memberships
Memberships
- American Society of Clinical Oncology
- American College of Physicians
- American Medical Association
- Chicago Medical Society
- Illinois State Medical Society
Publications
- Schwartzberg, L, Arena, F, Bienvenu, B, Kaplan EH, Camacho, Campos, Waymack, JP, Tagliaferri M, Chen M, Li D: A Randomized, Open-Label, Safety and Exploratory Efficacy Study of Kanglaite Injection plus Gemcitabine (K+G) versus Gemcitabine in Patients with Advanced Pancreatic Cancer. J Cancer. 2017 Jul 3;8(10): 1872-1883. doi:10.7150/jca. 15407. eCollection 2017.
- Magasi S, Mallick R, Menendez B, Patel J, Johnson ML, Kaplan E, Cella D: Not By Symptoms Alone: How People with Lung Cancer Think About Their Illness and its Treatment. Submitted (J Supp Onc), 2013.
- Magasi S, Mallick R, Kaiser K, Patel J, Lad T, Johnson M, Kaplan EH, Cella D: The Importance and Relevance of Pulmonary Symptoms Among Patients Receiving Second and Third-Line Treatment for Advanced Non-Small Cell Lung Cancer: Support for the Content Validity of the 4-Item Pulmonary Symptom Index. Clin Lung Cancer. 2013, May; 14(3):245-53. doi: 10.10116/jcllc.2012.07.001. Epub 2012 Oct 1.
- Butts CA, Bodkin D, Middleman EL, Englund CW, Ellison D, Alam Y, Kreisman H, Graze P, Maher J, Ross HJ, Ellis PM, McNulty W, Kaplan E, Pautret V, Weber MR, and Shepherd FA: A Randomized Phase II Study of Gemcitabine/Platinum With or Without Cetuximab As First-Line Therapy for Patients with Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC). Journal of Clinical Oncology, Vol 25, No 36 (December 20): 5777-5784, 2007.
- Kaplan, Edward and Velasco, Jose M.: Chapter 23 Oncology: D, Systemic Therapy. In: Rush University Medical Center Review of Surgery 4th ed., eds: Bines, S. et al.; Saunders/Elsevier, Inc. 261-267 ,2006.
- Sefert SA, Dart RC and Kaplan EH: Accidental, Intravenous Infusion of a Peanut Oil-Based Medication. J Toxicol Clin Toxicol 36(7): 733-736, 1998.
- Yellen SB, Cella DF, Webster K, Blendowski C, Kaplan EH, and Sarokhan B. Measuring Fatigue and Other Anemia Related Symptoms with the Functional Assessment of Cancer Therapy (FACT) Measurement System. Journal of Pain and Symptom Management. 13(2): 63-74, 1997.
- Lindemann K and Kaplan EH. Amifostine in the Management of Chemotherapy-Induced Neurotoxicity. ONS presentation, 1996.
- Martenson JA, Lipsitz S, Watner H, Kaplan EH, Otteman LA, Schuchter LM, Mansour EG, Talamonti MS, and Benson AB III. Initial Results of a Phase II Trial of High-Dose Radiation Therapy, 5-Fluorouracil, and Cisplatin for Patients with Anal Cancer (E4292): An Eastern Cooperative Oncology Group Study. Int J Radiat Oncol Biol Phys 35(4): 745-749, 1996.
- Cella DF, Bonomi AE, Lloyd SR, Tulsky DS, Kaplan EH, and Bonomi P: Reliability and Validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) Quality of Life Instrument. Lung Cancer. 12(3): 199-220, 1995.